At a glance
ClinicalIndex Comparison RecordN/ACompleted· 64 enrolled
Drug / intervention
GORE® EXCLUDER® Iliac Branch Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms
In Brief
A clinical study evaluating GORE® EXCLUDER® Iliac Branch Endoprosthesis for Common Iliac Artery Aneurysms and Aorto-iliac Aneurysms. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartOct 2013
Primary CompletionApr 2016
Study CompletionJun 2021
TodayJul 2026
First PostedJun 21, 2013
Enrollment StartOct 1, 2013
Primary CompletionApr 1, 2016
Study CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.0 years ago
Interventions
GORE® EXCLUDER® Iliac Branch Endoprosthesisdevice